Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2010

or

¨

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from
to

Commission File Number: 000-51902

INFUSYSTEM
HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

20-3341405

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

31700 Research Park Drive

Madison Heights, Michigan 48071

(Address of Principal Executive Offices including zip code)

(248) 291-1210

(Registrants Telephone Number, Include Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.
See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Securities Exchange Act.

Large Accelerated Filer ¨

Accelerated Filer ¨

Non-Accelerated Filer ¨ (Do not check if a smaller reporting company)

Smaller reporting company x

Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange
Act). Yes ¨ No x

As of August 5, 2010, 19,874,039 shares of the registrants common stock, par value $0.0001 per share, were outstanding.

Adjustments to reconcile net income to net cash provided by operating activities:

Loss on derivative liabilities

460

636

Gain on extinguishment of long-term debt

(1,118

)



Provision for doubtful accounts

2,469

1,844

Depreciation and loss on disposal of pumps

2,559

2,093

Amortization of intangible assets

991

914

Amortization of deferred debt issuance costs

834

264

Stock-based compensation

997

545

Deferred income taxes

(814

)

787

Changes in assets and liabilities, exclusive of effects of acquisitions:

Increase in accounts receivable, net of provision

(2,682

)

(2,653

)

Increase in other current assets

(404

)

(1,317

)

Increase in other assets

(860

)

(511

)

Increase in accounts payable and other liabilities

1,165

657

Decrease in derivative liabilities from termination of interest rate swap

(365

)



NET CASH PROVIDED BY OPERATING ACTIVITIES

3,364

3,512

INVESTING ACTIVITIES

Capital expenditures

(743

)

(2,672

)

Cash paid for acquisition, net of cash acquired

(16,418

)



Proceeds from sale of property



1

Other assets



(18

)

NET CASH USED IN INVESTING ACTIVITIES

(17,161

)

(2,689

)

FINANCING ACTIVITIES

Principal payments on term loan

(20,568

)

(6,929

)

Cash proceeds from term loan

30,000



Common stock repurchased to satisfy statutory withholding on Stock-based compensation

(38

)



Principal payments on capital lease obligation

(331

)

(43

)

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES

9,063

(6,972

)

Net change in cash and cash equivalents

(4,734

)

(6,149

)

Cash and cash equivalents, beginning of period

7,750

11,513

Cash and cash equivalents, end of period

3,016

5,364

SUPPLEMENTAL DISCLOSURES

Cash paid for interest (including swap payments)

$

1,226

$

1,533

Cash paid for income taxes

$

14

$

39

NON-CASH TRANSACTIONS

Additions to property (a)

$

111

$

1,002

Property acquired pursuant to a capital lease

$

1,372



Origination of long term debt

$

750



Current assets assumed in acquisition (b)

$

2,314



Current liabilities assumed in acquisition (b)

$

438



Deferred tax liability assumed in acquisition (b)

$

2,754

Deferred tax asset assumed in acquisition (b)

$

30

(a)

Amounts consist of current liabilities for net property that have not been included in investing activities. These amounts have not been paid for as of June 30,
2010 and 2009 but will be included as a cash outflow from investing activities for capital expenditures when paid.

The information in this Quarterly Report on Form 10-Q includes the financial position of InfuSystem Holdings, Inc. and its consolidated
subsidiaries (the Company) as of June 30, 2010 and December 31, 2009, the results of operations for the three and six months ended June 30, 2010 and 2009, and cash flows for the six months ended June 30, 2010 and
2009.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting
principles generally accepted in the United States of America (GAAP). All intercompany accounts and transactions have been eliminated. Results of operations for the three and six months ended June 30, 2010 are not necessarily
indicative of the results for an entire year.

The Company is a provider of infusion services to oncologists and other
outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Companys unique suite of services appeals to
practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes.

On June 15, 2010, the Company entered into a stock purchase agreement with the shareholders of First Biomedical, Inc., (First
Biomedical) a Kansas corporation, to acquire all of the issued and outstanding stock of First Biomedical and completed the acquisition. First Biomedical sells, rents, services and repairs new and pre-owned infusion pumps and other medical
equipment. First Biomedical also sells a variety of primary and secondary tubing, cassettes, catheters and other disposable items that are utilized with infusion pumps. For more information, please refer to the Acquisition discussion
included in Note 3.

To the Companys knowledge, it is the largest ambulatory infusion pump management service provider
to oncology practices in the United States. The Company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology practices, infusion clinics and hospital outpatient chemotherapy clinics. These pumps and
supplies are utilized primarily by colorectal cancer patients who receive a standard of care treatment that utilizes continuous chemotherapy infusions delivered via electronic ambulatory infusion pumps. The Company obtains an assignment of insurance
benefits from the patient, bills the insurance company or patient accordingly, and collects payment. The Company provides pump management services for the pumps and associated disposable supply kits to over 1,300 oncology practices in the United
States. The Company retains title to the pumps during this process.

In addition, the Company sells or rents new and pre-owned
pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for, oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing
facilities, pain centers and others. The company also provides these products and services to customers in the small-hospital market.

The Company purchases new and pre-owned pole mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis.
The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Companys ambulatory infusion pump management service.

The Company has one operating segment, representing the only reportable segment in accordance with Accounting Standard Codification
(ASC) 280 (formerly Statement of Financial Accounting Standards (SFAS) No. 131, Disclosures about Segments of an Enterprise and Related Information).

The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany
transactions and account balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that
affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated
financial statements, including the following: revenue recognition, which includes contractual allowances; accounts receivable and allowance for doubtful accounts; income taxes; and goodwill valuation. Management relies on historical experience and
other assumptions believed to be reasonable in making its judgment and estimates. Actual results could differ materially from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company
maintains its cash and cash equivalents primarily with a single financial institution and is fully insured with the Federal Deposit Insurance Corporation (FDIC) under the Transaction Account Guarantee Program (which has been extended until
December 31, 2010).

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at the estimated net realizable amounts from patients, third-party payors and other direct pay customers
for goods provided and services rendered. The Company performs periodic analyses to assess the accounts receivable balances. It records an allowance for doubtful accounts based on the estimated collectability of the accounts such that the recorded
amounts reflect estimated net realizable value. Upon determination that an account is uncollectible, the account is written-off and charged to the allowance.

Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. The Companys estimate
for its allowance for doubtful accounts is based upon managements assessment of historical and expected net collections by payor. Due to continuing changes in the health care industry and third-party reimbursement it is possible that
managements estimates could change in the near term, which could have an impact on its financial position, results of operations, and cash flows.

Inventory Supplies

Our
Inventory consists of infusion pumps and related parts and supplies and is stated at the lower of cost (determined on a first in, first out basis) or market. The Company records a period expense for inventory supplies obsolescence when incurred.

Property and Equipment

Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the
related assets, ranging from three to seven years. Rental equipment, consisting primarily of infusion pumps that the Company acquires from third-parties, is depreciated over five years. Leasehold improvements are amortized using the straight-line
method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated
depreciation are removed from the accounts and any gain or loss is recorded in the current period.

Long-Lived Assets

The Company accounts for the impairment and disposition of long-lived assets in accordance with ASC 360, (formerly SFAS No. 144,
Accounting for Impairment or Disposal of Long-Lived Assets). This standard

addresses financial accounting and reporting for the impairment of long-lived assets and for the disposal of long-lived assets. In accordance with this standard, long-lived assets to be held are
reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset (or asset group) for recoverability. Recoverability of these assets
is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing managements best estimates, appropriate assumptions and projections at the time. If the carrying value is
determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset. The Company reviews
the carrying value of long-lived assets if there is an indicator of impairment. The Company has determined that no impairment indicators existed as of June 30, 2010.

Goodwill Valuation

Goodwill arising from business combinations represents the excess of the purchase price over the estimated fair value of the net assets of
the businesses acquired.

In accordance with the provisions of ASC 350 (formerly SFAS No. 142, Goodwill and Other
Intangible Assets), goodwill is tested annually for impairment or more frequently if circumstances indicate the possibility of impairment. Significant judgments required to estimate fair value include estimating future cash flows, and
determining appropriate discount rates, growth rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value which could trigger impairment. The Company performed the annual
impairment test at October 31, 2009, and determined there was no impairment of goodwill. No events have occurred subsequent to October 31, 2009 that indicates impairment may have occurred.

Intangible Assets

Intangible assets consist of trade names, physician and customer relationships, non-compete agreements and software. The trade names,
physician and customer relationships and non-compete agreements arose from the acquisitions of InfuSystem and First Biomedical. Software is amortized on a straight-line basis over 3 years. The Company amortizes the value assigned to the physician
and customer relationships on a straight-line basis over the period of expected benefit, which is 15 years. The acquired physician and customer relationship base represents a valuable asset of InfuSystem due to the expectation of future business
opportunities to be leveraged from the existing relationship with each physician and customer. InfuSystem has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing facilities,
pain centers and others. These relationships are expected, on average, to have a 15 year useful life, based on minimal attrition experienced to date by the Company and expectations of continued minimal attrition. Management tests non-amortizable
intangible assets (trade names) for impairment in accordance with ASC 350 (formerly SFAS No. 142). The Company performed the annual impairment test at October 31, 2009, and determined there was no impairment. No events have occurred
subsequent to October 31, 2009 that indicates impairment may have occurred.

Revenue Recognition

The majority of the Companys revenue is rental revenue in the oncology market. Revenues are recognized predominantly under fee for
service arrangements through equipment that the Company rents to patients. The Company recognizes revenue only when all of the following criteria are met: persuasive evidence of an arrangement exists; services have been rendered; the price to the
customer is fixed or determinable; and collectability is reasonably assured. Persuasive evidence of an arrangement is determined to exist, and collectability is reasonably assured, when the Company receives a physicians written order and
assignment of benefits, signed by the physician and patient, respectively, and the Company has verified actual pump usage and insurance coverage. The Company recognizes rental revenue from electronic infusion pumps as earned, normally on a
month-to-month basis. Pump rentals are billed at the Companys established rates, which often differ from contractually allowable rates provided by third-party payors such as Medicare, Medicaid and commercial insurance carriers. All billings to
third party payors are recorded net of provision for contractual adjustments to arrive at net revenues.

Due to the nature of
the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have
to be revised or updated as additional information becomes

available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to
amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, it is possible that managements estimates could change in the near term, which could have an impact on our results of operations
and cash flows.

The Companys largest contracted payor is Medicare, which accounted for approximately 31% of its gross
billings for the six months ended June 30, 2010. The Company has contracts with various individual Blue Cross/Blue Shield affiliates which in the aggregate accounted for approximately 23% of its gross billings for the six months ended
June 30, 2010. No individual payor (other than Medicare and the Blue Cross/Blue Shield entities) accounts for greater than approximately 6% of the Companys gross billings.

The Company also recognizes revenue for selling, renting and servicing new and pre-owned infusion pumps and other medical equipment.
Revenue is recognized when goods are provided or services are rendered.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740 (formerly SFAS No. 109, Accounting for Income Taxes), which
requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the
differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than
not that some or all of any deferred tax assets will not be realized. For more information, please refer to the Income Taxes discussion included in Note 8.

Share Based Payment

ASC
718 (formerly SFAS No. 123(R), Share-Based Payment), requires all entities to recognize compensation expense in an amount equal to the fair value of share based payments made to employees, among other requirements. Under the fair value
based method, compensation cost is measured at the grant date based on the fair value of the award and is recognized on a straight-line basis over the award vesting period. Accordingly, share based payments issued to officers and directors are
measured at fair value and recognized as expense over the related vesting periods.

In 2007, the Company adopted the 2007
Stock Incentive Plan (the Plan) providing for the issuance of a maximum of 2,000,000 shares of common stock in connection with the grant of stock-based or stock-denominated awards. In addition, during the three and six months ended
June 30, 2010, the Company made certain grants of restricted stock outside of the Plan.

During the three and six months
ended June 30, 2010, the Company granted 3,425,000 restricted shares. Of the total shares granted, 1,425,000 entitle a holder to receive, at the end of a vesting period, a specified number of shares of the Companys common stock. The
remaining 2,000,000 shares granted entitle the holder to receive common stock when the shares vest based upon certain market conditions tied to the Companys stock price, or certain performance conditions including a change in control.

Share based compensation expense recognized for the three and six months ended June 30, 2010 was $897,000 and $997,000,
respectively, compared to $268,000 and $545,000 for each of the three and six months ended June 30, 2009, respectively.

Warrants and
Derivative Financial Instruments

On April 18, 2006, the Company consummated its initial public offering
(IPO) of 16,666,667 units. Each unit consists of one share of common stock and two redeemable common stock purchase warrants. Each warrant entitles the holder to purchase from the Company one share of its common stock at an exercise
price of $5.00. On May 18, 2006, the Company sold an additional 208,584 units (the Overallotment Units) to FTN Midwest Securities Corp., the underwriter of its IPO (FTN Midwest), pursuant to a partial exercise by FTN
Midwest of its overallotment option. The Warrant Agreement provides for the Company to register the shares underlying the warrants in the absence of the Companys ability to deliver registered shares to the warrant holders upon warrant
exercise.

In September 2000, the Emerging Issues Task Force issued ASC 815 (formerly EITF 00-19,
Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in, a Companys Own Stock), which requires freestanding derivative contracts that are settled in a companys own stock, including common stock
warrants, to be designated as equity instruments, assets or liabilities. Under the provisions of this standard, a contract designated as an asset or a liability must be carried at its fair value on a companys balance sheet, with any changes in
fair value recorded in the companys results of operations. A contract designated as an equity instrument must be included within equity, and no fair value adjustments are required from period to period.

On February 16, 2010 the Company announced an Offer to Exchange common stock for outstanding warrants. At the time, the Company had
35,108,219 outstanding warrants. The exchange offer expired on March 17, 2010. Holders of the Companys warrants had the option to exchange their warrants for either One (1) share of Common Stock for every thirty-five
(35) Warrants tendered, or One (1) share of Common Stock for every twenty-five (25) Warrants tendered, provided the recipient agreed to be subject to a lock-up provision precluding transfer of the shares of Common Stock received for
six months following the expiration of the Exchange Offer. Based on the final count, 25,635,723 Warrants were properly tendered; 24,766,700 were tendered for shares of Common Stock subject to a lock-up, and 869,023 were tendered for unrestricted
shares of Common Stock. Under the terms of the Exchange Offer, the Company issued an aggregate 1,015,489 shares of Common Stock in exchange for the tendered Warrants. After the exchange, there are 8,329,638 publicly held warrants and 1,142,858
privately held warrants outstanding.

In accordance with ASC 815, the 8,329,638 remaining warrants issued in connection with
the IPO and overallotment to purchase common stock must be settled in registered shares and are separately accounted for as liabilities as discussed in Note 6. The fair value of these warrants is shown on the Companys balance sheet and the
unrealized changes in the value of these warrants are shown in the Companys statement of operations as (Loss) gain on derivatives. These warrants are freely traded on the Over the Counter Bulletin Board. Consequently,
the fair value of these warrants is estimated as the market price of the warrant at each period end. To the extent the market price increases or decreases, the Companys warrant liabilities will also increase or decrease with a corresponding
impact on the Companys results of operations within Loss on derivatives.

Sales of warrants that can be
settled in unregistered shares of common stock, as discussed in Note 10, are treated as equity and included in additional paid in capital. The total warrants issued to date that can be settled in unregistered shares of common stock are 1,142,858 at
an issue price of $.70 per warrant or a total issue price of $800,000.

ASC 815 (formerly SFAS No. 133, Accounting for
Derivative Instruments and Hedging Activities), requires that an entity recognize all derivatives as either assets or liabilities in the statement of financial position and measure those instruments at fair value.

Deferred Debt Issuance Costs

Capitalized debt issuance costs as of June 30, 2010 relate solely to the Companys recently completed Bank of America credit
facility, while as of December 31, 2009 they relate solely to the Companys term loan with Kimberly-Clark (formerly I-Flow). The Company classifies the costs related to the Bank of America credit facility as non-current assets and
amortizes them using the interest method through the maturity date of June 2014. For a further discussion of the Companys deferred debt issuance costs, please see Note 7.

Earnings Per Share

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the
period. Diluted earnings per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted earnings per share computations:

For the three and six months ended June 30, 2010 the following warrants and stock
options were not included in the calculation because they would have an anti-dilutive effect: 8,329,638 outstanding warrants issued in connection with the IPO, 1,142,858 warrants issued privately and 100,479 vested stock options. For the three and
six months ended June 30, 2009 the following warrants and stock options were not included in the calculation because they would have an anti-dilutive effect: 33,750,502 outstanding warrants issued in connection with the IPO and 1,357,717
warrants issued privately, and 75,000 in vested stock options and 225,000 in non-vested stock options.

Subsequent events

The Company adopted the provisions of ASC 855 effective June 15, 2009 and, other than the interest rate swap entered into as
described in Note 6, management has concluded that there are no other significant subsequent events requiring disclosure through August 6, 2010, which is the date the consolidated financial statements were issued.

3.

Acquisitions

Entry into a Material
Definitive Agreement

On June 15, 2010, the Company entered into a stock purchase agreement with the shareholders of
First Biomedical, Inc., a Kansas corporation, (First Biomedical) to acquire all of the issued and outstanding stock of First Biomedical and completed the acquisition for total consideration of $17,213,000. Included in the consideration
is $16,463,000 paid in cash and a $750,000 seller note described in further detail below.

First Biomedical sells, rents,
services and repairs new and pre-owned infusion pumps and other medical equipment. First Biomedical also sells a variety of primary and secondary tubing, cassettes, catheters and other disposable items that are utilized with infusion pumps.
Headquartered in Olathe, KS, with additional facilities in California and Toronto, First Biomedical is a leading provider to alternate site healthcare facilities and hospitals in the United States and Canada. The acquisition of First Biomedical
allows the Company to expand its offerings to existing customers with the addition of biomedical service and repair, while simultaneously bolstering the growth of infusion pump sales within the oncology space and beyond.

First Biomedicals results of operations are included in the Companys consolidated statements of operations from the
acquisition date.

Pursuant to ASC 805, Business Combinations, the purchase price has been allocated to the assets acquired and liabilities assumed based
upon their estimated fair values as of the acquisition date. The purchase price allocation was primarily based upon a valuation using income and cost approaches, and managements estimates and assumptions. The excess of the purchase price over
the net tangible and identifiable intangible assets was recorded as goodwill. For tax purposes, goodwill consists of both identifiable intangible assets (customer relationships and non-competition agreements from the table below) and unidentifiable
intangible assets (goodwill from the table below). Goodwill is expected to be partially deductible for tax purposes. The purchase price allocation is based on a preliminary analysis and is subject to further adjustments. The allocation of the
purchase price to the fair values of the assets acquired and liabilities assumed as of the transaction date is presented below (in thousands):

The stock purchase agreement provides for an adjustment to the purchase price based on final
working capital as of the closing balance sheet, which has not yet been finalized.

Acquired property and equipment are being
depreciated on a straight-line basis with estimated remaining lives ranging from 1 year to 14.5 years. Intangible assets are being amortized on a straight-line basis with estimated remaining lives ranging from 5 to 15 years reflecting the expected
future value.

Fees

During the six months ended June 30, 2010, we incurred legal and professional fees directly related to the First Biomedical
acquisition totaling approximately $785,000. All such costs are presented under the caption General and administrative within operating expenses in the accompanying consolidated statements of operations.

Seller Note

Pursuant to
the terms of the Stock Purchase Agreement, as of the date of the acquisition the Company entered into a subordinated promissory note with the former majority shareholder of First Biomedical (the Seller) in the amount of $750,000. In
accordance with the note, the Company will pay the Seller in equal installments over 24 months, which includes annual interest of 5%.

Pro
Forma Financial Information

The pro forma financial information in the table below summarizes the combined results of
operations of the Company and First Biomedical as though the companies had been combined as of the beginning of each period presented. The pro forma financial information is presented for informational purposes only and is not indicative of the
results of operations that would have been achieved if the acquisition had taken place at the beginning of each period presented nor is it indicative of future results. The following pro forma financial information for all periods presented also
includes the pro forma depreciation and amortization charges from acquired tangible and intangible assets, and related tax effects:

Six Months Ended June 30,

2010

2009

Net revenues

$

26,508

$

23,065

Net income

497

561

Earnings per share - basic

0.03

0.03

Earnings per share - diluted

0.02

0.03

InfuSystem Acquisition - Additional
Contingent Payment

The Stock Purchase Agreement related to the acquisition of InfuSystem provides for a potential
additional payment of up to $12,000,000, or the earn-out, to I-Flow in 2011, provided that certain consolidated net revenue growth targets related to the Companys operations are met. Any amounts ultimately paid out in 2011 per the
earn-out would increase Goodwill at the time of payment. No additional payment will be made unless the Company achieves consolidated net revenue CAGR of at least 40% over the three-year period. The consolidated net revenue CAGR for the two-year
period ended December 31, 2009, as compared to InfuSystems 2007 net revenues, was 11%.

4.

Property and Equipment

Property and equipment consisted of the following as of June 30, 2010 and December 31, 2009 (amounts in thousands):

Included in pump equipment above is $4,050,000 and $2,678,000, as of
June 30, 2010 and December 31, 2009, respectively, worth of pumps obtained under various capital leases. Included in accumulated depreciation above is $603,000 and $278,000, as of June 30, 2010 and December 31, 2009,
respectively, associated with the same capital leases. Under the terms of all such capital leases, the Company does not presently hold title to these pumps, and will not obtain title until such time as the capital lease obligations are settled in
full.

Depreciation expense for the three and six months ended June 30, 2010 was $1,171,000 and $2,343,000, respectively,
which was recorded in cost of revenues and general and administrative expenses, for pump equipment and other fixed assets, respectively.

5.

Goodwill and Intangible Assets

Goodwill

Goodwill
arising from business combinations represents the excess of the purchase price over the estimated fair value of the net assets of the businesses acquired. The goodwill amount for the October 25, 2007 acquisition of InfuSystem is $56,580,000,
and is based upon the final valuation analysis. The goodwill amount for the June 15, 2010 acquisition of First Biomedical is $7,488,000, and is based upon a preliminary valuation analysis and is subject to change until the valuation analysis is
final.

Impairment Testing

As of October 31, 2009, the Company performed its annual impairment test pursuant to ASC 350 (formerly SFAS No. 142, Goodwill
and Other Intangible Assets). The fair value of the Companys single reporting unit was estimated using a combined income (discounted cash flow) and market approach (guideline public company) valuation model which indicated that the fair
value of its net assets exceeded the carrying value. Based on the results of the valuation, the Company determined there was no impairment of goodwill. No events have occurred subsequent to October 31, 2009 that indicates impairment may have
occurred.

The Company has continued to monitor operational performance measures, general economic conditions and its market
capitalization. A downward trend in one or more of these factors could cause the Company to reduce the estimated fair value of its reporting unit and recognize a corresponding impairment of goodwill in connection with a future goodwill impairment
test.

The Company tests non-amortizable intangible assets (trade names) for impairment in accordance with ASC 350. The
Company performed the annual impairment test at October 31, 2009, and determined there was no impairment. No events have occurred subsequent to October 31, 2009 that indicates impairment may have occurred. The intangible assets resulting
from the October 25, 2007 acquisition of InfuSystem are based upon the final valuation analysis. The intangible assets resulting from the June 15, 2010 acquisition of First Biomedical are based upon the preliminary valuation analysis and
are subject to change.

Identifiable Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of June 30, 2010 and December 31, 2009 were as follows
(in thousands):

Amortization expense for intangible assets for the three and six months ended June 30,
2010 was $534,000 and $991,000, respectively, compared to $457,000 and $914,000, respectively, for the three and six months ended June 30, 2009, which was recorded in operating expenses. Expected annual amortization expense for intangible
assets recorded as of June 30, 2010 is as follows (in thousands):

2010

2011

2012

2013

2014

Amortization expense

$

2,368

$

2,606

$

2,475

$

2,311

$

2,281

6.

Warrants and Derivative Financial Instruments

The Company has determined that the warrants discussed in Note 2, issued in connection with the IPO including the Overallotment Units,
should be classified as liabilities in accordance with ASC 815 (formerly EITF 00-19). Therefore, the fair value of each instrument must be recorded as a liability on the Companys balance sheet. Changes in the fair values of these instruments
will result in adjustments to the amount of the recorded liabilities, and the corresponding gain or loss will be recorded in the Companys statement of operations within (Loss) gain on derivatives. At the date of the conversion of
each warrant or portion thereof (or exercise of the warrants or portion thereof, as the case may be), the corresponding liability will be reclassified as equity.

On February 16, 2010 the Company announced an Offer to Exchange common stock for outstanding warrants. At the time, the Company had
35,108,219 outstanding warrants. The exchange offer expired on March 17, 2010. Holders of the Companys warrants had the option to exchange their warrants for either One (1) share of Common Stock for every thirty-five
(35) Warrants tendered, or One (1) share of Common Stock for every twenty-five (25) Warrants tendered, provided the recipient agreed to be subject to a lock-up provision precluding transfer of the shares of Common Stock received for
six months following the expiration of the Exchange Offer. Based on the final count, 25,635,723 Warrants were properly tendered; 24,766,700 were tendered for shares of Common Stock subject to a lock-up, and 869,023 were tendered for unrestricted
shares of Common Stock. Under the terms of the Exchange Offer, the Company issued an aggregate of 1,015,489 shares of Common Stock in exchange for the tendered Warrants. There are 8,329,638 publicly held warrants (issued in connection with the IPO)
and 1,142,858 privately held warrants remaining after the exchange.

The fair value of the Companys 8,329,638 and
33,750,502 warrants issued in connection with the IPO outstanding at June 30, 2010 and December 31, 2009, respectively, were liabilities of $750,000 or $0.09 per warrant and $2,025,000 or $0.06 per warrant, respectively.

On June 11, 2010, the Company terminated the single interest rate swap agreement that fixed its LIBOR-based variable rate on the
Kimberly-Clark (I-Flow) loan. The interest rate swap was terminated through a cash settlement in the amount of $365,000, which was the fair value of the interest rate swap as of the date of the termination. The fair value of the Companys
interest rate swap outstanding at December 31, 2009 was a liability of $645,000. The Company elected not to designate the swap as a cash flow hedge, in accordance with ASC 815. The fair value of the swap was therefore shown on the
Companys consolidated balance sheet and the unrealized changes in the value of the swap are shown in the Companys consolidated statement of operations within (Loss) gain on derivatives.

On July 20, 2010, the Company put in place a single interest rate swap with a
July 30, 2010 effective date. The interest rate swap agreement, which expires in June 2014, has a notional value of $19,500,000 at inception and a fixed rate of 1.40%.

Total derivative liabilities are as follows (in thousands):

June 30,2010

December 31,2009

Warrant liability

$

750

$

2,025

Interest rate swap liability



645

Total

$

750

$

2,670

Fair Value Measurements at Reporting Date Using

Description

June 30,2010

Quoted Prices inActive Markets forIdentical Liabilities(Level 1)

SignificantOtherObservableInputs(Level 2)

SignificantUnobservableInputs(Level 3)

Warrant liability

$

750

$

750

$



$



Interest rate swap liability





Total

$

750

$

750



Fair Value Measurements at Reporting Date Using

Description

December 31,2009

Quoted Prices inActive Markets forIdentical Liabilities(Level 1)

SignificantOtherObservableInputs(Level 2)

SignificantUnobservableInputs(Level 3)

Warrant liability

$

2,025

$

2,025

$



$



Interest rate swap liability

$

645



645



Total

$

2,670

$

2,025

$

645



7.

Debt and other Long-term Obligations

On June 15, 2010, the Company entered into a credit facility with Bank of America, N.A. as Administrative Agent, and KeyBank National
Association as Documentation Agent. The facility consists of a $30,000,000 term loan and a $5,000,000 revolving credit facility, both of which mature in June 2014. Interest on the term loan is payable at the Companys choice of LIBOR plus 4.5%,
or the Bank of America prime rate plus 3.5%. As of June 30, 2010, interest was payable at LIBOR plus 4.5%, which equaled approximately 4.85%.

Proceeds from the new term loan have been used to repay the outstanding balance of the Companys debt held by Kimberly-Clark
(I-Flow), as well as contribute to the acquisition consideration for First Biomedical. As of June 30, 2010, the Company had no borrowings on its revolving credit facility.

The new term loan is collateralized by substantially all of the Companys assets and requires the Company to comply with covenants,
including but not limited to, financial covenants relating to satisfaction of a total leverage ratio, a fixed charge coverage ratio, and an annual limit on capital expenditures. As of June 30, 2010, the Company believes it was in compliance
with all such covenants.

In conjunction with the new credit facility, the Company incurred deferred debt issuance costs of
$808,000. These costs will be recognized in income using the effective interest method through the maturity date of June 15, 2014. Amortization of these costs for both the three and six months ended June 30, 2010 was $4,000 which was
recorded in interest expense. Also, the Company incurred deferred debt issuance costs in conjunction with the Kimberly-Clark (I-Flow) loan. The remaining unamortized I-Flow debt costs were completely amortized when the term loan was paid in full on
June 15, 2010. Total amortization expense for the three and six months ended June 30, 2010 were $727,000 and $834,000, respectively.

In conjunction with the acquisition of First Biomedical, the Company entered into a
subordinated promissory note with the former majority shareholder of First Biomedical (the Seller) in the amount of $750,000. In accordance with the note, the Company will pay the Seller in equal installments over 24 months, which
includes annual interest of 5%.

The Company sometimes enters into capital leases to finance the purchase of ambulatory
infusion pumps. The pumps are capitalized into property and equipment at their fair market value, which equals the value of the future minimum lease payments, and are depreciated over the useful life of the pumps.

Maturities on the loans and capital lease are as follows (in thousands):

7/1/1012/31/10

2011

2012

2013

Thereafter

Total

Term Loan

$

1,875

$

4,125

$

4,500

$

4,875

$

14,625

$

30,000

Seller Note

181

375

194





750

Capital Lease

436

947

1,033

944

136

3,496

Total

$

2,492

$

5,447

$

5,727

$

5,819

$

14,761

$

34,246

8.

Income Taxes

Provision
for income taxes was a benefit of $717,000 and $407,000 for the three and six months ended June 30, 2010, respectively, as compared to a benefit of $261,000 and $121,000 for the three and six months ended June 30, 2009. In computing its
income tax provision, the Company estimates its effective income tax rate for the full year and applies that rate to income earned through the reporting period. The Company also reflected certain discrete items in its tax provision for the
quarter. The income tax benefit for the three and six months ended June 30, 2010 is primarily related to the release of a $942,000 valuation allowance previously established against existing deferred tax assets. Without the release of
the valuation allowance the Company would have reported a tax expense of approximately $225,000 for the three months ended June 30, 2010 and a tax expense of approximately $535,000 for the six months ended June 30, 2010.

On June 15, 2010, the Company acquired the stock of First Biomedical, Inc. In accordance with ASC 805, Business
Combinations, the fair value of the consideration was allocated to the net assets acquired adjusting the book value of the acquired assets to their fair market value. As this was a stock acquisition, the Companys tax basis of
the assets acquired did not change. This differential resulted in the recording of deferred tax liabilities of $2,754,000 in connection with the First Biomedical assets. These new deferred tax liabilities, which are a source of future taxable
income, provide strong evidence in support of the valuation allowance reversal.

The Companys realization of its
deferred tax assets is dependent upon many factors, including, but not limited to, the Companys ability to generate sufficient taxable income. Certain deferred tax liabilities can also be considered as a source of future taxable income
including those resulting from the acquisition. In prior years and through March 31, 2010, the Company had deferred tax assets to which a full valuation allowance was applied. At the end of the first quarter the total valuation
allowance was $942,000. Based upon the weight of available evidence, it was more likely than not that some portion or all of the deferred tax assets would not be realized. During the quarter ended June 30, 2010, as a result of a review of
the Companys earnings history, existing deferred tax liabilities including those resulting from the First Biomedical acquisition, the Company has removed the valuation allowance previously applied against the net deferred tax asset.

In 2006, the Company reserved in its treasury 2,000,000 shares of common stock for issuance to Sean McDevitt and 416,666 shares of common
stock for issuance to Pat LaVecchia. The consummation of the transaction resulted in 925,531 of these shares being issued at October 25, 2007. Of the remaining 1,491,135 shares, 257,091 were issued in 2008 and 1,234,044 were issued in February
2009.

Effective September 7, 2009, Steve Watkins resigned as Chief Executive Officer and Director of the Company. In
connection with Mr. Watkins resignation, the Board of Directors (the Board) has (i) appointed Sean McDevitt, the current Chairman of the Board, as Chief Executive Officer and (ii) formed an Executive Committee
consisting of Chairman Sean McDevitt, Wayne Yetter and John Voris, with Mr. McDevitt serving as Executive Chairman.

Prior to the Companys acquisition of InfuSystem, InfuSystem had been providing billing and collection services
to I-Flow for its ON-Q® product. On October 25, 2007, InfuSystem and I-Flow entered into an Amended and
Restated Services Agreement (the Services Agreement) pursuant to which InfuSystem agreed to continue to provide I-Flow with these services, and I-Flow agreed to pay InfuSystem a monthly service fee. During the three and six months ended
June 30, 2009, the Company recorded revenues of $44,000 and $155,000 from this arrangement. There was no revenues recorded for the three and six months ended June 30, 2010 and there was no outstanding receivable amount due as of
June 30, 2010.

On November 8, 2007, I-Flow informed the Company that it was terminating the Services Agreement
effective May 10, 2008. In May 2008, both parties extended and amended the Services Agreement for one month, upon substantially the same terms and conditions as the original agreement. From June 2008 through December 1, 2008, the parties
operated without a written agreement upon substantially the same terms and conditions as the original Services Agreement, with the exception that the original 40% mark-up was increased to 50%. On December 2, 2008, the Company agreed with I-Flow
to extend the Services Agreement to September 30, 2009. Pursuant to the terms of the extension, the service fee paid to the Company through January 31, 2009 was calculated based on a 50% mark up. Effective February 1, 2009 through
June 30, 2009, the service fee was equal to 30% of the total actual net cash collections (net of adjustments) received during such month on behalf of I-Flow. I-Flow also reimbursed the Company monthly for the portion of the Companys lease
cost associated with the office space dedicated to this operation. Effective July 1, 2009 the Company and I-Flow agreed to continue the services arrangement on a month to month basis, during which time I-Flow reimbursed the Company the greater
of 30% of net cash collections or $3,000. The service was discontinued effective August 31, 2009.

In connection
with the warrant exchange as described in Note 6 to these consolidated financial statements, three present Company board members exchanged 186,287 privately held warrants under the lock-up provision for 7,451 shares of common stock.

As described in Note 7 to these consolidated financial statements, in accordance with the terms of the Stock Purchase Agreement with
First Biomedical, the Company entered into a subordinated promissory note with the former majority shareholder of First Biomedical (the Seller) in the amount of $750,000. In accordance with the note, the Company will pay the Seller in
equal installments over 24 months, which includes annual interest of 5%. The Seller is a current employee of the Company. Also, the Seller owns Jan-Mar LLC and is the principal owner of the CW Investment Group LLC. In accordance with the Stock
Purchase Agreement, the Company entered into operating lease agreements with Jan-Mar LLC and the CW Investment Group LLC, each of which owns one of the two office buildings utilized by First Biomedical in Olathe, Kansas. The terms of each lease is
thirty six months, commencing on July 1, 2010. Rent will be paid monthly in the amount of $5,000 to Jan-Mar LLC and $3,000 to the CW Investment Group LLC.

10.

Commitments and Contingencies

Certain of the Companys directors committed to purchase up to $1,000,000 of the Companys warrants from the Company in a
private placement at a price of $.70 per warrant subsequent to the filing of the preliminary proxy statement seeking stockholder approval of the acquisition of InfuSystem. Such officers and directors agreed not to sell or transfer the warrants until
after the Company consummated a business combination. The warrants have an exercise price of $5.00 per share of common stock and became exercisable commencing on October 25, 2007, the

acquisition date, and expire April 11, 2011 or earlier upon redemption by the Company. The Company may call the warrants for redemption in whole and not in part at a price of $0.01 per
warrant at anytime after the warrant becomes exercisable. The warrants cannot be redeemed unless the holder receives written notice not less than 30 days prior to the redemption and if and only if, the reported last price of the common stock equals
or exceeds $8.50 per share for any 20 trading days within a 30 day period ending on the third day of business prior to the notice of redemption to warrant holders. The Company has fully reserved the shares underlying the warrants as authorized but
not issued. The warrants issued and sold in 2006 and 2007 were not registered under the Securities Act of 1933, as amended (the Securities Act). As a result, the warrants and the common stock issuable upon exercise of the warrants may
not be sold unless they have been registered pursuant to a registration statement filed under the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act as evidenced by an opinion of counsel
reasonably satisfactory to the Company. There are 1,142,858 privately held warrants remaining after the exchange as discussed in Note 6 to these consolidated financial statements.

The Company is involved in legal proceedings arising out of the ordinary course and conduct of our business, the outcomes of which are
not determinable at this time. We have insurance policies covering such potential losses where such coverage is cost effective. In the Companys opinion, any liability that might be incurred by us upon the resolution of these claims and
lawsuits will not, in the aggregate, have a material adverse effect on the Companys consolidated financial position, results of operations or cash flows

Effective September 7, 2009, Steve Watkins resigned as Chief Executive Officer and Director of the Company. In connection with his
resignation, the Company entered into a separation agreement with Mr. Watkins in which the Company will pay Mr. Watkins his annual base salary of $310,500 for a period of two years following the resignation date in accordance with the
Companys regular payroll practices. Also, the Company agreed to pay a bonus in the amount of $150,000 for the 2009 calendar year within thirty days of the resignation date; such amount was paid in October 2009. The Company will continue
to pay for Mr. Watkins existing health insurance benefits for a period of two years following the resignation date. Additionally, any unvested portions of Mr. Watkins stock options and restricted share grants vested pro rata
based upon his services to the Company as Chief Executive Officer during the 2009 calendar year.

As of June 30, 2010,
the Company had approximate minimum future operating lease commitments of (in thousands):

2010

2011

2012

2013

$

157

$

308

$

183

$

50

11.

Share-based Compensation

2007
Stock Incentive Plan

In 2007, the Company adopted the 2007 Stock Incentive Plan (the Plan) providing for
the issuance of a maximum of 2,000,000 shares of common stock in connection with the grant of stock-based or stock-denominated awards. As of June 30, 2010, 22,000 common shares remained available for future grant under the Plan.

During the six months ended June 30, 2010 the Company granted restricted shares both under the Plan and outside of it, and during
the six months ended June 30, 2009 the Company granted restricted shares and stock options under the Plan.

During the
three and six months ended June 30, 2010, the Company granted 3,425,000 restricted shares. Of the total shares granted, 1,425,000 entitle a holder to receive, at the end of a vesting period, a specified number of shares of the Companys
common stock. The remaining 2,000,000 shares granted entitle the holder to receive common stock when the shares vest based upon certain market conditions tied to the Companys stock price, or certain performance conditions including a change in
control.

Restricted Shares

Restricted shares entitle the holder to receive, upon meeting certain vesting criteria, a specified number of shares of the Companys
common stock. Stock-based compensation cost of restricted shares is measured by the

market value of the Companys common stock on the date of grant. Compensation cost associated with certain restricted share grants also takes into account market conditions in its
measurement. The following table summarizes restricted share activity for the six months ended June 30, 2010:

Number
ofawards(Inthousands)

Weightedaveragegrantdate fairvalue

Unvested at January 1, 2010

324

$

2.86

Granted

3,425

$

2.50

Vested

(207

)

$

2.83

Vested shares forgone to satisfy minimum statutory withholding

(14

)

$

2.82

Forfeitures

(1

)

$

2.58

Unvested at June 30, 2010

3,527

$

2.52

As of June 30, 2010, there was $11,117,000 of pre-tax total unrecognized compensation cost
related to non-vested restricted shares, which will be adjusted for future forfeitures. The Company expects to recognize such cost over a period of approximately 15.5 years.

Stock Options

There
were no stock options granted during the six months ended June 30, 2010. During the six months ended June 30, 2009, the Company granted 30,000 stock options at an exercise price of $1.85 per share which was the market price on the date of
grant.

Stock-based compensation expense

The following table shows the total stock-based compensation expense, related to all of the Companys equity awards in accordance
with ASC 718 (in thousands):

The Company has defined contribution plans in which the company contributes a certain percentage of employee contributions. Such
contributions totaled $10,000 and $25,000 for the three and six months ended June 30, 2010, respectively. InfuSystem does not provide post-retirement or post-employment benefits to its employees.

Managements Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a
provider of infusion services to oncologists and other outpatient treatment settings. We provide pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. Our unique
suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes.

We supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology practices, infusion clinics and hospital
outpatient chemotherapy clinics. These pumps and supplies are utilized primarily by colorectal cancer patients who receive a standard of care treatment that utilizes continuous chemotherapy infusions delivered via electronic ambulatory infusion
pumps. We obtain an assignment of insurance benefits from the patient, bill the insurance company or patient accordingly, and collect payment. We provide pump management services for the pumps and associated disposable supply kits to over 1,300
oncology practices in the United States, and retain title to the pumps during this process.

We sell or rent new and pre-owned
pole mounted and ambulatory infusion pumps to, and provide biomedical recertification, maintenance and repair services for, oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing
facilities, pain centers and others.

On June 15, 2010, we entered into a stock purchase agreement with the shareholders
of First Biomedical, Inc., a Kansas corporation, to acquire all of the issued and outstanding stock of First Biomedical and completed the acquisition for total consideration of $17.2 million. First Biomedicals results of operations are
included in our consolidated statements of operations from the acquisition date.

First Biomedical sells, rents, services and
repairs new and pre-owned infusion pumps and other medical equipment. First Biomedical also sells a variety of primary and secondary tubing, cassettes, catheters and other disposable items that are utilized with infusion pumps. Headquartered in
Olathe, KS, with additional facilities in California and Toronto, First Biomedical is a leading provider to alternate site healthcare facilities and hospitals in the United States and Canada.

Results of Operations

Revenues

Our revenue is predominantly derived from our rental of ambulatory infusion pumps which are primarily used for continuous
infusion of chemotherapy drugs for patients with colorectal cancer. Our revenue for the quarter ended June 30, 2010 was $10,487,000, a 14% improvement compared to $9,173,000 for the quarter ended June 30, 2009. Our revenue for the six
months ended June 30, 2010 was $21,421,000, a 16% improvement compared to $18,400,000 for the six months ended June 30, 2009. The increase in revenues is primarily due to obtaining business at new customer facilities, as well as deeper
penetration into existing customer facilities.

Management anticipates that new revenue growth will come from continuing to
obtain business from new customer facilities, sales of additional products and services, as well as the expansion of the existing use of our ambulatory infusion pumps for the treatment of colorectal cancer, as well as head, neck and gastric cancer.
Revenue will also come from the newly acquired First Biomedical business  sales and rentals of pumps, supplies, and biomedical services  both within and outside of oncology.

Cost of Revenues

Cost
of revenues, which consists of product and supply costs, including freight costs for the transport of pumps and supplies to and from oncology practices, and depreciation on and disposals of our infusion pumps, was $2,967,000 for the quarter ended
June 30, 2010, a 30% increase compared to $2,278,000 for the quarter ended June 30, 2009. Our cost of revenues for the six months ended June 30, 2010 was $5,781,000, a 32% increase compared to $4,388,000 for the six months ended
June 30, 2009. The increases for both periods was primarily related to increased revenues, a slight shift in revenue mix, an increase in pump depreciation and higher pump repair and

maintenance costs. As a percentage of revenues, cost of revenues increased from 25% to 28% for the three months ended June 30, 2010, and from 24% to 27% for the six months ended
June 30, 2010, compared to the same periods in the prior year.

Selling and Marketing Expenses

For the quarter ended June 30, 2010, our selling and marketing expenses were $1,595,000, compared to $1,419,000 for the quarter ended
June 30, 2009. For the six months ended June 30, 2010, our selling and marketing expenses were $3,036,000, compared to $2,739,000 for the six months ended June 30, 2009. Selling and marketing expenses during these periods consisted of
sales salaries, commissions and associated fringe benefit and payroll-related items, marketing, share-based compensation, travel and entertainment and other miscellaneous expenses. As compared to the prior year, these expenses remained relatively
constant at 15% of revenues for the quarter ended June 30, 2010, and decreased slightly from 15% to 14% of revenues for the six months ended June 30, 2010.

General and Administrative Expenses

During the quarter ended June 30, 2010, our general and administrative expenses were $4,569,000, compared to $2,800,000 for the
quarter ended June 30, 2009. During the six months ended June 30, 2010, our general and administrative expenses were $7,905,000, compared to $5,910,000 for the six months ended June 30, 2009. Included in the totals for the three and
six months ended June 30, 2010 was approximately $785,000 in one-time costs related to the acquisition of First Biomedical. Recurring general and administrative expenses during these periods consisted primarily of administrative personnel
salaries, fringe benefits and payroll-related items, professional fees, share-based compensation, insurance and other miscellaneous expenses. The expenses in total, excluding those related to the First Biomedical acquisition, have increased from 31%
to 36% of revenues for the quarter ended June 30, 2010, and 32% to 33% for the six months ended June 30, 2010. The increases in both periods are primarily related to an increase in share-based compensation expense.

Other Income and Expenses

During the quarter ended June 30, 2010, we recorded a loss on derivatives of $71,000, compared to a gain of $2,006,000 during the
quarter ended June 30, 2009. The quarter ended June 30, 2010 loss included an unrealized loss from the change in the fair value of our warrants, partially offset by a realized gain on the termination of our single interest rate swap,
whereas the quarter ended June 30, 2009 gain included unrealized gains from both the change in the fair value of our warrants and the change in the fair value of our single interest rate swap.

During the six months ended June 30, 2010, we recorded a loss on derivatives of $460,000, compared to a loss of $636,000 during the
six months ended June 30, 2009. Included in the six months ended June 30, 2010 loss was a realized loss recorded in connection with the warrant exchange, an unrealized loss from the change in the fair value of our warrants, and a realized
gain on the termination of our single interest rate swap, whereas the six months ended June 30, 2009 loss included an unrealized loss from the change in the fair value of our warrants and an unrealized gain from the change in the fair value of
our single interest rate swap. For more information, please refer to the discussion under Summary of Significant Accounting PoliciesWarrants and Derivative Financial Instruments included in Note 2 and Warrants and Derivative
Financial Instruments included in Note 6 to our Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

During the quarter ended June 30, 2010, we recorded interest expense of $1,366,000, compared to $851,000 for the quarter ended
June 30, 2009. During the six months ended June 30, 2010, we recorded interest expense of $2,172,000, compared to $1,837,000 for the six months ended June 30, 2009. These amounts consist primarily of interest paid on our term loans,
the expensing of all remaining deferred debt issuance costs incurred in conjunction with the I-Flow loan, expense associated with the now terminated interest rate swap and interest expense on capital leases. The increase for both periods is
primarily the result of expensing all of the remaining I-Flow deferred debt issuance coasts, partially offset by a decrease in interest expense on the term loan with I-Flow and lower cash payments associated with our single interest rate swap.

During the three and six months ended June 30, 2010, we recorded an income tax benefit of $717,000 and $407,000
respectively, compared to a benefit of $261,000 and $121,000 during the three and six months ended June 30, 2009, respectively. The increased benefit is primarily due to the reversal of our deferred tax asset valuation allowance, as discussed in
Note 8 to our consolidated financial statements.

Management believes that there has been no material effect on our operations or financial condition as a result of inflation or changing
prices of our ambulatory infusion pumps during the period from December 31, 2009 through June 30, 2010.

Liquidity and Capital
Resources

As of June 30, 2010 we had cash resources of $3,016,000 compared to $7,750,000 at December 31, 2009.
The decrease in cash was primarily due to the acquisition of First Biomedical, partially offset by an increase in outstanding term debt and positive cash flow from operating activities.

Cash provided by operating activities for the six months ended June 30, 2010 was $3,364,000, compared to $3,512,000 for the six
months ended June 30, 2009. The decrease is primarily attributable to the cash settlement upon termination of our interest rate swap, partially offset by increased revenues.

Cash used in investing activities for the six months ended June 30, 2010 was $17,161,000, compared to $2,689,000 for the six months
ended June 30, 2009. The increase is primarily related to cash paid for the acquisition of First Biomedical, partially offset by lower purchases of infusion pumps, more extensive use of capital leases to acquire such equipment, and the
non-repeat of first half 2009 expenditures associated with both moving our office facilities and investments in customized software.

Cash provided by financing activities for the six months ended June 30, 2010 was $9,063,000, compared to $6,972,000 of cash used in
financing activities for the six months ended June 30, 2009. The increase is primarily related to a $9,432,000 increase in outstanding term debt including a lower excess cash flow principal prepayment, partially offset by higher principal
payments associated with capital leases.

As of June 30, 2010, we had cash and cash equivalents of $3,016,000, net
accounts receivable of $7,459,000 and net working capital (excluding derivative liabilities) of $3,883,000, a decrease compared to net working capital of $6,332,000 as of December 31, 2009. Management believes the current funds, together with
expected cash flows from ongoing operations as well as the new $5,000,000 undrawn revolving credit facility from Bank of America referred to below, are sufficient to fund our operations for at least the next 12 months.

On June 15, 2010, we entered into a credit facility with Bank of America, N.A. as Administrative Agent, and KeyBank National
Association as Documentation Agent. The facility consists of a $30,000,000 term loan and a $5,000,000 revolving credit facility, both of which mature in June 2014. Interest on the term loan is payable at our choice of LIBOR plus 4.5%, or the Bank of
America prime rate plus 3.5%. As of June 30, 2010, interest was payable at LIBOR plus 4.5%, which equaled approximately 4.85%.

Proceeds from the new term loan have been used to repay the outstanding balance of our debt held by Kimberly-Clark (I-Flow), as well as
contribute to the acquisition consideration for First Biomedical. As of June 30, 2010, we had no borrowings on our revolving credit facility.

The Bank of America term loan is collateralized by substantially all of our assets and requires us to comply with covenants principally
relating to satisfaction of a total leverage ratio, a fixed charge coverage ratio, and an annual limit on capital expenditures. As of June 30, 2010, we believe we were in compliance with all such covenants.

Contractual Obligations

As of June 30, 2010, future payments related to contractual obligations are as follows (in thousands):

The table above does not include any potential payout to I-Flow associated with the earn-out provision in the Stock Purchase Agreement. For more information, please
refer to the discussion under Acquisitions included in Note 3 to our Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

(2)

The table above does not include any interest payments associated with our variable rate term debt. For more information, please refer to the discussion under
Debt and other Long-term Obligations included in Note 7 to our Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

Included in the operating lease obligations are future minimum lease payments as of June 30, 2010 under various lease agreement we
entered into for office space.

Contingent Liabilities

We do not have any contingent liabilities.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that
affect the amounts reported in the financial statements, including the notes thereto. We consider critical accounting policies to be those that require more significant judgments and estimates in the preparation of our consolidated financial
statements, including the following: revenue recognition, which includes contractual allowances; accounts receivable and allowance for doubtful accounts; warrants and derivative financial instruments; income taxes; and goodwill valuation. Management
relies on historical experience and other assumptions believed to be reasonable in making its judgment and estimates. Actual results could differ materially from those estimates.

Management believes its application of accounting policies, and the estimates inherently required therein, are reasonable. These
accounting policies and estimates are periodically reevaluated, and adjustments are made when facts and circumstances dictate a change.

Our accounting policies are more fully described under the heading Summary of Significant Accounting Policies in Note 2 to
our Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. We believe the following critical accounting estimates are the most significant to the presentation of our financial statements and require the most difficult,
subjective and complex judgments:

Revenue Recognition

The majority of our revenue is rental revenue in the oncology market. Revenues are recognized predominantly under fee for service
arrangements through equipment that we rent to patients. We recognize revenue only when all of the following criteria are met: persuasive evidence of an arrangement exists; services have been rendered; the price to the customer is fixed or
determinable; and collectability is reasonably assured. Persuasive evidence of an arrangement is determined to exist, and collectability is reasonably assured, when we receive a physicians written order and assignment of benefits, signed by
the physician and patient, respectively, and we have verified actual pump usage and insurance coverage. We recognize rental revenue from electronic infusion pumps as earned, normally on a month-to-month basis. Pump rentals are billed at our
established rates, which often differ from contractually allowable rates provided by third-party payors such as Medicare, Medicaid and commercial insurance carriers. All billings to third party payors are recorded net of provision for contractual
adjustments to arrive at net revenues.

Due to the nature of the industry and the reimbursement environment in which we operate,
certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.
Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Due to continuing changes in the
health care industry and third-party reimbursement, it is possible that managements estimates could change in the near term, which could have an impact on our results of operations and cash flows.

Our largest contracted payor is Medicare, which accounted for approximately 31% of its gross billings for the six months ended
June 30, 2010. We have contracts with various individual Blue Cross/Blue Shield affiliates which in the aggregate accounted for approximately 23% of its gross billings for the six months ended June 30, 2010. No individual payor (other than
Medicare and the Blue Cross/Blue Shield entities) accounts for greater than approximately 6% of our gross billings.

We also
recognize revenue for selling, renting and servicing new and pre-owned infusion pumps and other medical equipment. Revenue is recognized when goods are provided or services are rendered.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at the estimated net realizable amounts from patients, third-party payors and other direct pay customers
for goods provided and services rendered. We perform periodic analyses to assess the accounts receivable balances. It records an allowance for doubtful accounts based on the estimated collectability of the accounts such that the recorded amounts
reflect estimated net realizable value. Upon determination that an account is uncollectible, the account is written-off and charged to the allowance.

Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Our estimate for the allowance
for doubtful accounts is based upon managements assessment of historical and expected net collections by payor. Due to continuing changes in the health care industry and third-party reimbursement it is possible that managements estimates
could change in the near term, which could have an impact on its financial position, results of operations, and cash flows.

Share Based
Payment

ASC 718 (formerly SFAS No. 123(R), Share-Based Payment), requires all entities to recognize
compensation expense in an amount equal to the fair value of share based payments made to employees, among other requirements. Under the fair value based method, compensation cost is measured at the grant date based on the fair value of the award
and is recognized on a straight-line basis over the award vesting period. Accordingly, share based payments issued to officers and directors are measured at fair value and recognized as expense over the related vesting periods.

In 2007, we adopted the 2007 Stock Incentive Plan providing for the issuance of a maximum of 2,000,000 shares of common stock in
connection with the grant of stock-based or stock-denominated awards.

During the three and six months ended June 30,
2010, we granted 3,425,000 restricted shares. 1,425,000 of the granted shares entitle a holder to receive, at the end of a vesting period, a specified number of shares of the Companys common stock. The other 2,000,000 granted shares entitle
the holder to receive common stock when the granted shares vest based upon certain market conditions.

Share based
compensation expense recognized for the three and six months ended June 30, 2010 was $896,000 and $997,000, respectively, compared to $268,000 and $545,000 for each of the three and six months ended June 30, 2009, respectively.

On April 18, 2006, we consummated its initial public offering (IPO) of 16,666,667 units. Each unit consists of one share
of common stock and two redeemable common stock purchase warrants. Each warrant entitles the holder to purchase from us one share of its common stock at an exercise price of $5.00. On May 18, 2006, we sold an additional 208,584 units (the
Overallotment Units) to FTN Midwest Securities Corp., the underwriter of our IPO (FTN Midwest), pursuant to a partial exercise by FTN Midwest of its overallotment option. The Warrant Agreement provides for us to register the
shares underlying the warrants in the absence of the our ability to deliver registered shares to the warrant holders upon warrant exercise.

In September 2000, the Emerging Issues Task Force issued ASC 815 (formerly EITF 00-19, Accounting for Derivative Financial Instruments
Indexed to and Potentially Settled in, a Companys Own Stock), which requires freestanding derivative contracts that are settled in a companys own stock, including common stock warrants, to be designated as equity instruments, assets
or liabilities. Under the provisions of this standard, a contract designated as an asset or a liability must be carried at its fair value on a companys balance sheet, with any changes in fair value recorded in the companys results of
operations. A contract designated as an equity instrument must be included within equity, and no fair value adjustments are required from period to period.

On February 16, 2010 we announced an Offer to Exchange common stock for outstanding warrants. At the time, we had 35,108,219
outstanding warrants. The exchange offer expired on March 17, 2010. Holders of the our warrants had the option to exchange their warrants for either One (1) share of Common Stock for every thirty-five (35) Warrants tendered, or One
(1) share of Common Stock for every twenty-five (25) Warrants tendered, provided the recipient agreed to be subject to a lock-up provision precluding transfer of the shares of Common Stock received for six months following the expiration
of the Exchange Offer. Based on the final count, 25,635,723 Warrants were properly tendered; 24,766,700 were tendered for shares of Common Stock subject to a lock-up, and 869,023 were tendered for unrestricted shares of Common Stock. Under the terms
of the Exchange Offer, we issued an aggregate 1,015,489 shares of Common Stock in exchange for the tendered Warrants. After the exchange, there are 8,329,638 publicly held warrants and 1,142,858 privately held warrants outstanding.

In accordance with ASC 815, the 8,329,638 remaining warrants issued in connection with the IPO and overallotment to purchase common stock
must be settled in registered shares and are separately accounted for as liabilities as discussed in Note 6. The fair value of these warrants is shown on the our balance sheet and the unrealized changes in the value of these warrants are shown in
our statement of operations as (Loss) gain on derivatives. These warrants are freely traded on the Over the Counter Bulletin Board. Consequently, the fair value of these warrants is estimated as the market price of the
warrant at each period end. To the extent the market price increases or decreases, our warrant liabilities will also increase or decrease with a corresponding impact on our results of operations within Loss on derivatives.

Sales of warrants that can be settled in unregistered shares of common stock, as discussed in Note 10, are treated as equity and included
in additional paid in capital. The total warrants issued to date that can be settled in unregistered shares of common stock are 1,142,858 at an issue price of $.70 per warrant or a total issue price of $800,000.

ASC 815 (formerly SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities), requires that an entity
recognize all derivatives as either assets or liabilities in the statement of financial position and measure those instruments at fair value.

Income Taxes

We account
for income taxes in accordance with ASC 740 (formerly SFAS No. 109, Accounting for Income Taxes), which requires us to recognize deferred tax liabilities and assets based on the differences between the financial statement carrying
amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax
liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized. For more information, please refer to the Income Taxes
discussion included in Note 8.

Goodwill arising from business combinations represents the excess of the purchase price over the estimated fair value of the net assets of
the businesses acquired. In accordance with the provisions of SFAS No. 142, Goodwill and Other Intangible Assets, goodwill is tested annually for impairment or more frequently if circumstances indicate the possibility of impairment. We
performed the annual impairment test at October 31, 2009, and determined there was no impairment of goodwill. Management does not believe impairment of our goodwill existed at June 30, 2010.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

At June 30, 2010, the principal plus accrued interest on our term loan with Bank of America was $30,000,000. The term loan bears
interest at LIBOR plus 4.5% or the Bank of America prime rate plus 3.5%, at our option. The loan is a variable rate loan and therefore fair value approximates book value. Please see Note 7 to our Consolidated Financial Statements included in this
Quarterly Report on Form 10-Q for further discussion of our term loan with Bank of America.

We are exposed to interest rate
fluctuations on our underlying variable rate long-term debt. Until we terminated it effective June 11, 2010, we had utilized a single interest rate swap agreement to moderate the majority of such exposure related to our I-Flow debt. We do not
use derivative financial instruments for trading or other speculative purposes. At June 30, 2010, we did not have an interest rate swap agreement in effect to fix our LIBOR-based variable rate debt. On July 20, 2010, we put in place a
single interest rate swap with a July 30, 2010 effective date. The interest rate swap agreement, which expires in June 2014, had a notional value of $19,500,000 at inception and a fixed rate of 1.40%.

Based on the term loans outstanding and the swap which was in place through June 11, 2010, a decrease in LIBOR to zero (which is
less than a 100 basis point decrease) would have had no impact on our cash flow and pretax earnings for the three months ended June 30, 2010, and would have decreased our cash flow and pretax earnings for the six months ended June 30, 2010
by approximately $9,000. A 100 basis point increase in LIBOR would have increased our cash flow and pretax earnings for the three and six months ended June 30, 2010 by approximately $11,000 and $52,000, respectively.

We have classified certain warrants as derivative liabilities, which resulted in a liability of $750,000 at June 30, 2010. We
classified the warrants as derivative liabilities because there is a possibility that we may be required to settle the warrants in registered shares of common stock. We are required to compare the fair market value of these instruments from the date
of the initial recording to their fair market value as of the end of each reporting period and to reflect the change in fair market value in our Consolidated Statements of Operations as a gain or loss for the applicable period.

Item 4.

Controls and Procedures

Disclosure
Controls and Procedures

We maintain disclosure controls and procedures, (as defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934, as amended (the Exchange Act)) that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the SECs rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer (principal executive

officer) and Chief Financial Officer (principal accounting and financial officer), as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating
the disclosure controls and procedures, management recognizes that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the
inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been detected.

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with
the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2010. Based upon that evaluation,
our Chief Executive Officer and Chief Financial Officer each concluded that our disclosure controls and procedures are effective, at the reasonable assurance level, as of the end of the period covered by this Quarterly Report on Form 10-Q, as of
June 30, 2010.

Change in Internal Control

We have made no changes during six months ended June 30, 2010 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.

Stock Purchase Agreement, dated June 15, 2010, between InfuSystem Holdings, Inc. and First Biomedical, Inc. (filed as Exhibit 2.1 to the Registrants Current Report on
Form 8-K filed on June 18, 2010, and incorporated by reference herein)

10.1

Credit Agreement, dated June 15, 2010, among InfuSystem Holdings, Inc., InfuSystem, Inc. and First Biomedical, Inc. and Bank of America, N.A. and Keybank National
Association (filed as Exhibit 10.1 to the Registrants Current Report on Form 8-K filed on June 18, 2010, and incorporated by reference herein)

10.2

Share Award Agreement between the InfuSystem Holdings, Inc. and Sean McDevitt (filed as Exhibit 10.1 to the Registrants Current Report on Form 8-K filed April 9, 2010,
and incorporated by reference herein)

10.3

Restricted Stock Award Agreement between Sean Whelan and InfuSystem Holdings, Inc. (filed as Exhibit 4.1 to the Registrants Registration Statement on Form S-8 filed on
July 1, 2010 (Reg. No. 333-167914), and incorporated by reference herein)

10.4

Restricted Stock Award Agreement between Jan Skonieczny and InfuSystem Holdings, Inc. (filed as Exhibit 4.2 to the Registrants Registration Statement on Form S-8 filed on
July 1, 2010 (Reg. No. 333-167914), and incorporated by reference herein)

10.5

Restricted Stock Award Agreement between Bryan Russo and InfuSystem Holdings, Inc. (filed as Exhibit 4.3 to the Registrants Registration Statement on Form S-8 filed on
July 1, 2010 (Reg. No. 333-167914), and incorporated by reference herein)

10.6

Restricted Stock Award Agreement between David Haar and InfuSystem Holdings, Inc. (filed as Exhibit 4.4 to the Registrants Registration Statement on Form S-8 filed on
July 1, 2010 (Reg. No. 333-167914), and incorporated by reference herein)

10.7

Restricted Stock Award Agreement between Scott Chesky and InfuSystem Holdings, Inc. (filed as Exhibit 4.5 to the Registrants Registration Statement on Form S-8 filed on
July 1, 2010 (Reg. No. 333-167914), and incorporated by reference herein)

10.8

Restricted Stock Award Agreement between Timothy Kopra and InfuSystem Holdings, Inc. (filed as Exhibit 4.6 to the Registrants Registration Statement on Form S-8 filed on
July 1, 2010 (Reg. No. 333-167914), and incorporated by reference herein)

31.1

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002